Trial Profile
A retrospective study of incidence and risk factors associated with re-treatment after initial intravitreal Ranibizumab and photodynamic therapy in patients with polypoidal choroidal vasculopathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- 04 Apr 2017 New trial record